Patient-Focused Treatment Decisions in the Management of Overactive Bladder (OAB): Expert Strategies for Improved Clinical and Economic Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2021 Fall Managed Care Forum.
If you participated in the live session, you are not eligible for continuing
education credits from this archive.

This activity is valid from January 1, 2022, to March 1, 2023.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Astellas and Urovant Sciences

Overactive bladder (OAB) is a highly prevalent condition that approximately 17% of women and 16% of men over 18 suffer from, that’s an estimated 33 million people; however, the numbers may be higher due to undiagnosed cases. OAB occurs about twice as frequently in women as in men, and while OAB is not considered a normal part of aging, it does become more prevalent with advanced age. OAB has a significant impact on quality of life (QoL), comorbidities and cost; sufferers are two to three times more likely to experience disturbed sleep, overeating, poor self-esteem, and depression. Despite its impact, OAB remains underdiagnosed and undertreated. Screening and evaluating patients is of utmost importance in order to improve diagnosis and patient QoL. Patients are uncomfortable bringing up the subject and it falls to the physicians to make sure the topic is broached occasionally, while sometimes a patient will deny it quickly the first time asked out of embarrassment, the second time they may have reflected and be ready to accept screening and treatment. This activity on overactive bladder will provide medical directors, practicing physicians and nurses with important information regarding the consequences and clinical, societal, and economic burden of underdiagnosed and mismanaged overactive bladder, available data around the optimal cost and efficacy data around treatments and their side-effects, payer challenges and strategies to achieve optimal cost management and strategies for individualized therapy and improved patient adherence.

Upon completion of this activity, participants will be able to:

  • Quantify the clinical and economic burden of overactive bladder (OAB), including factors that contribute to poor prognosis and increased costs

  • Explore the pathophysiology, prevalence, and risk factors associated with overactive bladder (OAB) and recognize its impact on patients’ quality of life

  • Analyze the latest efficacy and safety data of new and emerging agents, including the antimuscarinics, beta-3 agonists and combination therapy, in the management of OAB

  • Examine the evolving role of beta-3 adrenergic receptor agonists in the management of OAB

  • Implement strategies to engage in more effective patient, provider and payer dialogues to identify the patient’s needs and improve outcomes for OAB

  • Analyze benefit design strategies for clinicians and managed care professionals to improve overall patient outcomes in OAB


Faculty: David Ginsberg, MD
Director, Neuro-urology and Female Urology
Clinical Professor of Urology
USC-Keck School of Medicine


Dr. Ginsberg serves as a consultant for Urovant. He has received grant/research support from Bioness, Procept, and Urovant. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Astellas and Urovant Sciences

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue